Aleksandra Soplińska

Dr. Aleksandra Soplińska


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2018 in Cells
Verified
Journal Article
Open access
PDF file
CECeren Eyileten
Ceren Eyileten
ZWZofia Wicik
Zofia Wicik
Salvatore De RosaSalvatore De Rosa
Salvatore De Rosa
DMDagmara M. Mirowska-Guzel
Dagmara M. Mirowska-Guzel
ASAleksandra Soplińska
Aleksandra Soplińska
MPMarek Postula
Marek Postula
Stroke is the second-most common cause of death worldwide. The pathophysiology of ischemic stroke (IS) is related to inflammation, atherosclerosis, blood coagulation, and platelet activation. MicroRNAs (miRNAs) play important roles in physiological and pathological processes of neurodegenerative diseases and progression of certain neurological diseases, such as IS. Several different miRNAs, and their target genes, are recognized to be involved in the pathophysiology of IS. The capacity of miRNAs to simultaneously regulate several target genes underlies their unique value as diagnostic and prognostic markers in IS. In this review, we focus on the role of miRNAs as diagnostic and prognostic biomarkers in IS. We discuss the most common and reliable detection methods available and promising tests currently under development. We also present original results from bioinformatic analyses of published results, identifying the ten most significant genes (HMGB1, YWHAZ, PIK3R1, STAT3, MAPK1, CBX5, CAPZB, THBS1, TNFRSF10B, RCOR1) associated with inflammation, blood coagulation, and platelet activation and targeted by miRNAs in IS. Additionally, we created miRNA-gene target interaction networks based on Gene Ontology (GO) information derived from publicly available databases. Among our most interesting findings, miR-19a-3p is the most widely modulated miRNA across all selected ontologies and might be proposed as novel biomarker in IS to be tested in future studies.

17 September 2020 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
CECeren Eyileten
Ceren Eyileten
LSLucia Sharif
Lucia Sharif
ZWZofia Wicik
Zofia Wicik
DJDaniel Jakubik
Daniel Jakubik
JJJoanna Jarosz-Popek
Joanna Jarosz-Popek
DMDagmara M. Mirowska-Guzel
Dagmara M. Mirowska-Guzel
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that plays a crucial role in the development of the nervous system while supporting the survival of existing neurons and instigating neurogenesis. Altered levels of BDNF, both in the circulation and in the central nervous system (CNS), have been reported to be involved in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), multiple sclerosis (MS), and ischemic stroke. MicroRNAs (miRNAs) are a class of non-coding RNAs found in body fluids such as peripheral blood and cerebrospinal fluid. Several different miRNAs, and their target genes, are recognized to be involved in the pathophysiology of neurodegenerative and neurovascular diseases. Thus, they present as promising biomarkers and a novel treatment approach for CNS disorders. Currently, limited studies provide viable evidence of miRNA-mediated post-transcriptional regulation of BDNF. The aim of this review is to provide a comprehensive assessment of the current knowledge regarding the potential diagnostic and prognostic values of miRNAs affecting BDNF expression and its role as a CNS disorders and neurovascular disease biomarker. Moreover, a novel therapeutic approach in neurodegenerative diseases and ischemic stroke targeting miRNAs associated with BDNF will be discussed.

13 October 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASAleksandra Soplińska
Aleksandra Soplińska
LZLukasz Zareba
Lukasz Zareba
ZWZofia Wicik
Zofia Wicik
CECeren Eyileten
Ceren Eyileten
DJDaniel Jakubik
Daniel Jakubik
MPMarek Postula
Marek Postula
Endurance sports have an unarguably beneficial influence on cardiovascular health and general fitness. Regular physical activity is considered one of the most powerful tools in the prevention of cardiovascular disease. MicroRNAs are small particles that regulate the post-transcription gene expression. Previous studies have shown that miRNAs might be promising biomarkers of the systemic changes in response to exercise, before they can be detected by standard imaging or laboratory methods. In this review, we focused on four important physiological processes involved in adaptive changes to various endurance exercises (namely, cardiac hypertrophy, cardiac myocyte damage, fibrosis, and inflammation). Moreover, we discussed miRNAs’ correlation with cardiopulmonary fitness parameter (VO2max). After a detailed literature search, we found that miR-1, miR-133, miR-21, and miR-155 are crucial in adaptive response to exercise.

4 May 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CECeren Eyileten
Ceren Eyileten
ASAleksandra Soplińska
Aleksandra Soplińska
JPJustyna Pordzik
Justyna Pordzik
JSJolanta M. Siller-Matula
Jolanta M. Siller-Matula
MPMarek Postula
Marek Postula

1 April 2020 in Journal Of Hypertension
Verified
Journal Article
Closed access
EWEwa Warchoł-Celińska
Ewa Warchoł-Celińska
KPKrzysztof Pieluszczak
Krzysztof Pieluszczak
MPMarco Pappaccogli
Marco Pappaccogli
ASAleksandra Soplińska
Aleksandra Soplińska
APAleksander Prejbisz
Aleksander Prejbisz
MJMagdalena Januszewicz
Magdalena Januszewicz
Objective: Visceral artery fibromuscular dysplasia (VA FMD) manifestations range from asymptomatic to life-threatening. The aim of the study is to evaluate the prevalence and clinical characteristics of VA FMD. Methods: A total of 232 FMD patients enrolled into ongoing ARCADIA-POL study were included in this analysis. All patients underwent detailed clinical evaluation including ambulatory blood pressure monitoring, biobanking, duplex Doppler of carotid and abdominal arteries and whole body angio-computed tomography. Three control groups (patients with renal FMD without visceral involvement, healthy normotensive patients and resistant hypertensive patients) matched for age and sex were included. Results: VA FMD was present in 32 patients (13.8%). Among these patients (women: 84.4%), FMD lesions were more frequent in celiac trunk (83.1%), 62.5% of patients showed at least one visceral aneurysm, and five patients presented with severe complications related to VA FMD. No demographic differences were found between patients with VA FMD and individuals from the three control groups, with the exception of lower weight (P < 0.001) and BMI (P < 0.001) in VA FMD patients. Patients with FMD (with or without visceral artery involvement) showed significantly smaller visceral arterial diameters compared with controls without FMD. Conclusion: Patients with FMD showed smaller visceral arterial diameters when compared with patients without FMD. This may reflect a new phenotype of FMD, as a generalized arteriopathy, what needs further investigation. Lower BMI in patients with VA FMD might be explained by chronic mesenteric ischemia resulting from FMD lesions. FMD visceral involvement and visceral arterial aneurysms in patients with renal FMD are far to be rare. This strengthens the need for a systematic evaluation of all vascular beds, including visceral arteries, regardless of initial FMD involvement.

1 April 2019 in Vascular Pharmacology
Verified
Journal Article
Closed access
Aleksandra GąseckaAleksandra Gąsecka
Aleksandra Gąsecka
MKMichał Konwerski
Michał Konwerski
JPJustyna Pordzik
Justyna Pordzik
ASAleksandra Soplińska
Aleksandra Soplińska
KFKrzysztof J. Filipiak
Krzysztof J. Filipiak
MPMarek Postula
Marek Postula